Can-Fite BioPharma Ltd.(CANF)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $3.8M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
CANF Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Can-Fite BioPharma Ltd. (CANF), a Healthcare sector company. CANF is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $3.8m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (FY 2025), Can-Fite BioPharma Ltd. reports quarterly revenue of $405.0K, net income of $-9.8M, free cash flow of $-9.0M. Top institutional holders of CANF by reported 13-F value include CITADEL ADVISORS, RHUMBLINE ADVISERS, FIFTH THIRD BANCORP, based on the most recent SEC filings. CANF trades on the NYSE exchange and files with the SEC under CIK 1536196. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CANF daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Can-Fite BioPharma Ltd. directly from SEC EDGAR.
Revenue
FY 2025
$405.0K
Net Income
FY 2025
$-9.8M
Free Cash Flow
FY 2025
$-9.0M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
-39.9% YoYNet Income
-24.7% YoYOperating Income
-22.4% YoYEPS (Diluted)
+45.0% YoYTotal Assets
+4.3% YoYOp. Cash Flow
-17.2% YoYFree Cash Flow
-17.1% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $405.0K -39.9% | $674.0K -9.3% | $743.0K -8.3% | $810.0K -5.0% | $853.0K +11.8% | $763.0K |
| Net Income | $-9.8M -24.7% | $-7.9M -3.2% | $-7.6M +25.0% | $-10.2M +19.4% | $-12.6M +12.7% | $-14.4M |
| Operating Income | $-9.9M -22.4% | $-8.1M +0.8% | $-8.2M +18.8% | $-10.1M +21.4% | $-12.8M +9.2% | $-14.1M |
| EPS (Diluted) | $-5.97 +45.0% | $-10.86 +39.4% | $-17.92 -179100.0% | $-0.01 +66.7% | $-0.03 +25.0% | $-0.04 |
| Total Assets | $9.5M +4.3% | $9.1M -8.7% | $10.0M +7.6% | $9.3M -54.2% | $20.3M +112.7% | $9.5M |
| Operating Cash Flow | $-8.9M -17.2% | $-7.6M +9.5% | $-8.4M +21.9% | $-10.8M -9.6% | $-9.9M +18.3% | $-12.1M |
| Free Cash Flow | $-9.0M -17.1% | $-7.6M +9.5% | $-8.4M +21.9% | $-10.8M -9.5% | $-9.9M +18.4% | $-12.1M |
Get alerted when CANF's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Can-Fite BioPharma Ltd. including:
Top Institutional Holders of CANF
CITADEL ADVISORS LLC
$96.6K32,533 shRHUMBLINE ADVISERS
$51.8K17,433 shFIFTH THIRD BANCORP
$446.00150 shWELLS FARGO & COMPANY/MN
$175.0059 shActivest Wealth Management
$30.0010 shTD Waterhouse Canada Inc.
$4.001 shMORGAN STANLEY
$3.001 shAvion Wealth
$0.005 sh
| Fund | Value | Shares |
|---|---|---|
| CITADEL ADVISORS LLC | $96.6K | 32,533 |
| RHUMBLINE ADVISERS | $51.8K | 17,433 |
| FIFTH THIRD BANCORP | $446.00 | 150 |
| WELLS FARGO & COMPANY/MN | $175.00 | 59 |
| Activest Wealth Management | $30.00 | 10 |
| TD Waterhouse Canada Inc. | $4.00 | 1 |
| MORGAN STANLEY | $3.00 | 1 |
| Avion Wealth | $0.00 | 5 |
More Healthcare Companies
View all Healthcare →Put CANF on your watchlist
Track score changes the day Can-Fite BioPharma Ltd. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is CANF a good stock to buy?
13F Pro's AI-powered analysis of Can-Fite BioPharma Ltd. (CANF) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CANF are available on the CANF stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. CANF is classified as a small company.
Which hedge funds own CANF?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CANF. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Can-Fite BioPharma Ltd.'s investment landscape.